Replies to post #32690 on Fuse Science Inc (DROP)

[infoseeker11]

Traveling right now. Page 5. Fuse has completed four stages thus far with Macular. The final stage and commercialization is planned for early 2013.

[Baystbully]

In support of our licensing efforts, there are a series of potential product formulations in various categories that are being contemplated or are in development through defined project platforms. It is anticipated that these formulations will be licensed and supplied to industry leaders in their respective categories. Immediate areas of focus include, but are not limited to:

Rx Applications
· Insulin
· Estradiol
· Paclitaxel
· Niacin
· Nicotine

OTC Applications
· Aspirin
· Caffeine
· Folic Acid
· Vitamin E
· Niacin
· Anti-Aging Skin Care
· Analgesics
· Allergy
· Cough and Cold
· Sleep Aids
· Appetite Suppressants
· Complex Nutraceuticals

In August 2012, we entered into a letter of intent with Macular Health, LLC (“Macular”), a leading manufacturer and distributor of macular degeneration nutritional supplements to license our proprietary delivery technology for the development of DROP formulations of Macular’s products. As of the date of this report, we have advanced through four stages of product development and currently are preparing final formulations for clinical testing, which we anticipate will be facilitated by Macular in early 2013.